{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T07:43:26Z","timestamp":1746258206981,"version":"3.37.3"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T00:00:00Z","timestamp":1642809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T00:00:00Z","timestamp":1642809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s10147-021-02098-1","type":"journal-article","created":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T13:02:22Z","timestamp":1642856542000},"page":"495-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Perspectives on the role of breast cancer susceptibility gene in breast cancer"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3630-3372","authenticated-orcid":false,"given":"Nan","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinpu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juntian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,22]]},"reference":[{"key":"2098_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3322\/caac.21203","volume":"64","author":"C DeSantis","year":"2014","unstructured":"DeSantis C, Ma J, Bryan L et al (2014) Breast cancer statistics, 2013. CA Cancer J Clin 64:52\u201362","journal-title":"CA Cancer J Clin"},{"key":"2098_CR2","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1054\/bjoc.2000.1407","volume":"83","author":"Anglian Breast Cancer Study Group","year":"2000","unstructured":"Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83:1301\u20131308","journal-title":"Br J Cancer"},{"issue":"6","key":"2098_CR3","doi-asserted-by":"publisher","first-page":"vi31","DOI":"10.1093\/annonc\/mdr373","volume":"22","author":"J Balmana","year":"2011","unstructured":"Balmana J, Diez O, Rubio IT et al (2011) BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol Off J Eur Soc Med Oncol 22(6):vi31\u2013vi34","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2098_CR4","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S0140-6736(94)91578-4","volume":"343","author":"D Ford","year":"1994","unstructured":"Ford D, Easton DF, Bishop DT et al (1994) Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet 343:692\u2013695","journal-title":"Lancet"},{"key":"2098_CR5","first-page":"467","volume":"10","author":"JM Satagopan","year":"2001","unstructured":"Satagopan JM, Offit K, Foulkes W et al (2001) The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 10:467\u2013473","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2098_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10689-004-9554-y","volume":"3","author":"MJ Casey","year":"2004","unstructured":"Casey MJ, Bewtra C (2004) Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations. Fam Cancer 3:265\u2013281","journal-title":"Fam Cancer"},{"key":"2098_CR7","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1080\/13543784.2017.1318847","volume":"26","author":"M Robert","year":"2017","unstructured":"Robert M, Frenel JS, Gourmelon C et al (2017) Olaparib for the treatment of breast cancer. Expert Opin Investig Drugs 26:751\u2013759","journal-title":"Expert Opin Investig Drugs"},{"key":"2098_CR8","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117\u20131130","journal-title":"Am J Hum Genet"},{"key":"2098_CR9","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol Off J Am Soc Clin Oncol 25:1329\u20131333","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2098_CR10","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105:812\u2013822","journal-title":"J Natl Cancer Inst"},{"key":"2098_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.6004\/jnccn.2017.0003","volume":"15","author":"MB Daly","year":"2017","unstructured":"Daly MB, Pilarski R, Berry M et al (2017) NCCN guidelines insights: genetic\/familial high-risk assessment: breast and ovarian, version 2.2017. J Natl Compr Canc Netw 15:9\u201320","journal-title":"J Natl Compr Canc Netw"},{"key":"2098_CR12","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.5858\/arpa.2011-0035-RA","volume":"135","author":"KB Geiersbach","year":"2011","unstructured":"Geiersbach KB, Samowitz WS (2011) Microsatellite instability and colorectal cancer. Arch Pathol Lab Med 135:1269\u20131277","journal-title":"Arch Pathol Lab Med"},{"key":"2098_CR13","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/502306a","volume":"502","author":"A Ashworth","year":"2013","unstructured":"Ashworth A, Hudson TJ (2013) Genomics: comparisons across cancers. Nature 502:306\u2013307","journal-title":"Nature"},{"key":"2098_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12920-017-0244-7","volume":"10","author":"N Jalkh","year":"2017","unstructured":"Jalkh N, Chouery E, Haidar Z et al (2017) Next-generation sequencing in familial breast cancer patients from Lebanon. BMC Med Genomics 10:8","journal-title":"BMC Med Genomics"},{"key":"2098_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12920-015-0092-2","volume":"8","author":"A Kluska","year":"2015","unstructured":"Kluska A, Balabas A, Paziewska A et al (2015) New recurrent BRCA1\/2 mutations in Polish patients with familial breast\/ovarian cancer detected by next generation sequencing. BMC Med Genomics 8:19","journal-title":"BMC Med Genomics"},{"key":"2098_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ijc.30692","volume":"141","author":"GT Lang","year":"2017","unstructured":"Lang GT, Shi JX, Hu X et al (2017) The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: screening of 2,991 patients and 1,043 controls by next-generation sequencing. Int J Cancer 141:129\u2013142","journal-title":"Int J Cancer"},{"key":"2098_CR17","first-page":"2548","volume":"54","author":"CS Cropp","year":"1994","unstructured":"Cropp CS, Nevanlinna HA, Pyrhonen S et al (1994) Evidence for involvement of BRCA1 in sporadic breast carcinomas. Can Res 54:2548\u20132551","journal-title":"Can Res"},{"key":"2098_CR18","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2741\/4230","volume":"19","author":"A Paul","year":"2014","unstructured":"Paul A, Paul S (2014) The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers. Front Biosci (Landmark Ed) 19:605\u2013618","journal-title":"Front Biosci (Landmark Ed)"},{"key":"2098_CR19","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1016\/j.yexcr.2006.06.014","volume":"312","author":"KD Mirchandani","year":"2006","unstructured":"Mirchandani KD, D\u2019Andrea AD (2006) The Fanconi anemia\/BRCA pathway: a coordinator of cross-link repair. Exp Cell Res 312:2647\u20132653","journal-title":"Exp Cell Res"},{"key":"2098_CR20","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","volume":"31","author":"S Loi","year":"2013","unstructured":"Loi S, Sirtaine N, Piette F et al (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02\u201398. J Clin Oncol Off J Am Soc Clin Oncol 31:860\u2013867","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2098_CR21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pages F, Sautes-Fridman C et al (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:298\u2013306","journal-title":"Nat Rev Cancer"},{"key":"2098_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ijrobp.2004.05.069","volume":"61","author":"E Ceilley","year":"2005","unstructured":"Ceilley E, Jagsi R, Goldberg S et al (2005) Radiotherapy for invasive breast cancer in North America and Europe: results of a survey. Int J Radiat Oncol Biol Phys 61:365\u2013373","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2098_CR23","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2001.19.5.1539","volume":"19","author":"A Recht","year":"2001","unstructured":"Recht A, Edge SB, Solin LJ et al (2001) Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol Off J Am Soc Clin Oncol 19:1539\u20131569","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2098_CR24","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1158\/1535-7163.MCT-15-0243","volume":"14","author":"C Bartholomeusz","year":"2015","unstructured":"Bartholomeusz C, Xie X, Pitner MK et al (2015) MEK inhibitor selumetinib (AZD6244; ARRY-142886) prevents lung metastasis in a triple-negative breast cancer xenograft model. Mol Cancer Ther 14:2773\u20132781","journal-title":"Mol Cancer Ther"},{"key":"2098_CR25","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1158\/0008-5472.CAN-12-1699","volume":"73","author":"KN Stevens","year":"2013","unstructured":"Stevens KN, Vachon CM, Couch FJ (2013) Genetic susceptibility to triple-negative breast cancer. Can Res 73:2025\u20132030","journal-title":"Can Res"},{"key":"2098_CR26","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.2174\/0929867323666161214114948","volume":"24","author":"SP Basourakos","year":"2017","unstructured":"Basourakos SP, Li L, Aparicio AM et al (2017) Combination platinum-based and DNA damage response-targeting cancer therapy: evolution and future directions. Curr Med Chem 24:1586\u20131606","journal-title":"Curr Med Chem"},{"key":"2098_CR27","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1146\/annurev-med-050913-022545","volume":"66","author":"CJ Lord","year":"2015","unstructured":"Lord CJ, Tutt AN, Ashworth A (2015) Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev Med 66:455\u2013470","journal-title":"Annu Rev Med"},{"key":"2098_CR28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J et al (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379:753\u2013763","journal-title":"N Engl J Med"},{"key":"2098_CR29","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.6004\/jnccn.2018.7031","volume":"16","author":"TG Lyons","year":"2018","unstructured":"Lyons TG, Robson ME (2018) Resurrection of PARP inhibitors in breast cancer. J Natl Compr Canc Netw 16:1150\u20131156","journal-title":"J Natl Compr Canc Netw"},{"key":"2098_CR30","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377:523\u2013533","journal-title":"N Engl J Med"},{"key":"2098_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41416-018-0127-5","volume":"119","author":"NM Tung","year":"2018","unstructured":"Tung NM, Garber JE (2018) BRCA1\/2 testing: therapeutic implications for breast cancer management. Br J Cancer 119:141\u2013152","journal-title":"Br J Cancer"},{"key":"2098_CR32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/annonc\/mdx505","volume":"29","author":"HS Han","year":"2018","unstructured":"Han HS, Dieras V, Robson M et al (2018) Veliparib with temozolomide or carboplatin\/paclitaxel versus placebo with carboplatin\/paclitaxel in patients with BRCA1\/2 locally recurrent\/metastatic breast cancer: randomized phase II study. Ann Oncol 29:154\u2013161","journal-title":"Ann Oncol"},{"key":"2098_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41523-017-0052-4","volume":"3","author":"JK Litton","year":"2017","unstructured":"Litton JK, Scoggins M, Ramirez DL et al (2017) A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer 3:49","journal-title":"NPJ Breast Cancer"},{"key":"2098_CR34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","volume":"19","author":"S Loibl","year":"2018","unstructured":"Loibl S, O\u2019Shaughnessy J, Untch M et al (2018) Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 19:497\u2013509","journal-title":"Lancet Oncol"},{"key":"2098_CR35","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC et al (2013) Signatures of mutational processes in human cancer. Nature 500:415\u2013421","journal-title":"Nature"},{"key":"2098_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2017.10.002","volume":"38","author":"MD Nicola","year":"2017","unstructured":"Nicola MD, Apetoh L, Bellone M et al (2017) Innovative therapy, monoclonal antibodies and beyond. Cytokine Growth Factor Rev 38:1","journal-title":"Cytokine Growth Factor Rev"},{"key":"2098_CR37","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.jaci.2018.10.021","volume":"142","author":"ZK Ballas","year":"2018","unstructured":"Ballas ZK (2018) The 2018 nobel prize in physiology or medicine: an exemplar of bench to bedside in immunology. J Allergy Clin Immunol 142:1752\u20131753","journal-title":"J Allergy Clin Immunol"},{"key":"2098_CR38","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-017-0403-5","volume":"10","author":"J Wang","year":"2017","unstructured":"Wang J, Yuan R, Song W et al (2017) PD-1, PD-L1 (B7\u2013H1) and tumor-site immune modulation therapy: the historical perspective. J Hematol Oncol 10:34","journal-title":"J Hematol Oncol"},{"key":"2098_CR39","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/cas.12986","volume":"107","author":"Y He","year":"2016","unstructured":"He Y, Rivard CJ, Rozeboom L et al (2016) Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci 107:1193\u20131197","journal-title":"Cancer Sci"},{"key":"2098_CR40","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","volume":"72","author":"SR Woo","year":"2012","unstructured":"Woo SR, Turnis ME, Goldberg MV et al (2012) Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 72:917\u2013927","journal-title":"Cancer Res"},{"key":"2098_CR41","doi-asserted-by":"publisher","first-page":"v611","DOI":"10.1093\/annonc\/mdx440.011","volume":"28","author":"PA Ascierto","year":"2017","unstructured":"Ascierto PA, Bono P, Bhatia S et al (2017) Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti\u2013PD-1\/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. Ann Oncol 28:v611","journal-title":"Ann Oncol"},{"key":"2098_CR42","doi-asserted-by":"publisher","first-page":"9503","DOI":"10.1200\/JCO.2021.39.15_suppl.9503","volume":"39","author":"EJ Lipson","year":"2021","unstructured":"Lipson EJ, Tawbi AH, Schadendorf D et al (2021) Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: primary phase III results from RELATIVITY-047 (CA224-047). J Clin Oncol 39:9503\u20139503","journal-title":"J Clin Oncol"},{"key":"2098_CR43","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1200\/JCO.2018.36.15_suppl.3012","volume":"36","author":"S David","year":"2018","unstructured":"David S, Hong PS, Aitana C et al (2018) Phase I\/II study of LAG525 \u00b1 spartalizumab (PDR001) in patients (pts) with advanced malignancies. J Clin Oncol 36:3012\u20133012","journal-title":"J Clin Oncol"},{"key":"2098_CR44","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","volume":"25","author":"S Loi","year":"2014","unstructured":"Loi S, Michiels S, Salgado R et al (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol Off J Eur Soc Med Oncol 25:1544\u20131550","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2098_CR45","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1200\/JCO.2001.19.2.329","volume":"19","author":"S Menard","year":"2001","unstructured":"Menard S, Valagussa P, Pilotti S et al (2001) Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol Off J Am Soc Clin Oncol 19:329\u2013335","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2098_CR46","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nrclinonc.2010.59","volume":"7","author":"JW Moul","year":"2010","unstructured":"Moul JW (2010) Radiotherapy: secondary malignancies after prostate cancer treatment. Nat Rev Clin Oncol 7:249\u2013250","journal-title":"Nat Rev Clin Oncol"},{"key":"2098_CR47","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723","journal-title":"N Engl J Med"},{"key":"2098_CR48","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1158\/1078-0432.CCR-19-3545","volume":"26","author":"P Narayan","year":"2020","unstructured":"Narayan P, Wahby S, Gao JJ et al (2020) FDA approval summary: atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1. Clin Cancer Res 26:2284\u20132289","journal-title":"Clin Cancer Res"},{"key":"2098_CR49","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.annonc.2019.11.010","volume":"31","author":"R Barroso-Sousa","year":"2020","unstructured":"Barroso-Sousa R, Jain E, Cohen O et al (2020) Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Ann Oncol 31:387\u2013394","journal-title":"Ann Oncol"},{"key":"2098_CR50","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1093\/annonc\/mdy399","volume":"29","author":"B Szekely","year":"2018","unstructured":"Szekely B, Bossuyt V, Li X et al (2018) Immunological differences between primary and metastatic breast cancer. Ann Oncol 29:2232\u20132239","journal-title":"Ann Oncol"},{"key":"2098_CR51","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","volume":"6","author":"R Nanda","year":"2020","unstructured":"Nanda R, Liu MC, Yau C et al (2020) Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol 6:676\u2013684","journal-title":"JAMA Oncol"},{"key":"2098_CR52","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382:810\u2013821","journal-title":"N Engl J Med"},{"key":"2098_CR53","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","volume":"30","author":"S Loibl","year":"2019","unstructured":"Loibl S, Untch M, Burchardi N et al (2019) A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 30:1279\u20131288","journal-title":"Ann Oncol"},{"key":"2098_CR54","doi-asserted-by":"publisher","first-page":"e4975","DOI":"10.1097\/MD.0000000000004975","volume":"95","author":"Z Baretta","year":"2016","unstructured":"Baretta Z, Mocellin S, Goldin E et al (2016) Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis. Medicine (Baltimore) 95:e4975","journal-title":"Medicine (Baltimore)"},{"key":"2098_CR55","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s10549-017-4552-6","volume":"167","author":"RC Brianese","year":"2018","unstructured":"Brianese RC, Nakamura KDM, Almeida F et al (2018) BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation. Breast Cancer Res Treat 167:803\u2013814","journal-title":"Breast Cancer Res Treat"},{"key":"2098_CR56","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa1400382","volume":"371","author":"AC Antoniou","year":"2014","unstructured":"Antoniou AC, Casadei S, Heikkinen T et al (2014) Breast-cancer risk in families with mutations in PALB2. N Engl J Med 371:497\u2013506","journal-title":"N Engl J Med"},{"key":"2098_CR57","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1038\/srep04026","volume":"4","author":"JM Cunningham","year":"2014","unstructured":"Cunningham JM, Cicek MS, Larson NB et al (2014) Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. Sci Rep 4:4026","journal-title":"Sci Rep"},{"key":"2098_CR58","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/annonc\/mdw142","volume":"27","author":"M Moschetta","year":"2016","unstructured":"Moschetta M, George A, Kaye SB et al (2016) BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol 27:1449\u20131455","journal-title":"Ann Oncol"},{"key":"2098_CR59","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/1097-0142(19890315)63:6<1084::AID-CNCR2820630608>3.0.CO;2-U","volume":"63","author":"KS Sridhar","year":"1989","unstructured":"Sridhar KS, Hussein AM, Feun LG et al (1989) Activity of pirarubicin (4\u2019-0-tetrahydropyranyladriamycin) in malignant mesothelioma. Cancer 63:1084\u20131091","journal-title":"Cancer"},{"key":"2098_CR60","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264","journal-title":"Nat Rev Cancer"},{"key":"2098_CR61","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ et al (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677\u2013704","journal-title":"Annu Rev Immunol"},{"key":"2098_CR62","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1002\/eji.200324228","volume":"33","author":"SC Liang","year":"2003","unstructured":"Liang SC, Latchman YE, Buhlmann JE et al (2003) Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 33:2706\u20132716","journal-title":"Eur J Immunol"},{"key":"2098_CR63","first-page":"409","volume":"84","author":"DB Flies","year":"2011","unstructured":"Flies DB, Sandler BJ, Sznol M et al (2011) Blockade of the B7\u2013H1\/PD-1 pathway for cancer immunotherapy. Yale J Biol Med 84:409\u2013421","journal-title":"Yale J Biol Med"},{"key":"2098_CR64","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y et al (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99:12293\u201312297","journal-title":"Proc Natl Acad Sci USA"},{"key":"2098_CR65","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","volume":"54","author":"C Blank","year":"2005","unstructured":"Blank C, Gajewski TF, Mackensen A (2005) Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 54:307\u2013314","journal-title":"Cancer Immunol Immunother"},{"key":"2098_CR66","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","volume":"14","author":"R Berger","year":"2008","unstructured":"Berger R, Rotem-Yehudar R, Slama G et al (2008) Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res Off J Am Assoc Cancer Res 14:3044\u20133051","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2098_CR67","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol Off J Am Soc Clin Oncol 28:3167\u20133175","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2098_CR68","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134\u2013144","journal-title":"N Engl J Med"},{"key":"2098_CR69","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454","journal-title":"N Engl J Med"},{"key":"2098_CR70","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0952-7915(02)00341-2","volume":"14","author":"RJ Greenwald","year":"2002","unstructured":"Greenwald RJ, Latchman YE, Sharpe AH (2002) Negative co-receptors on lymphocytes. Curr Opin Immunol 14:391\u2013396","journal-title":"Curr Opin Immunol"},{"key":"2098_CR71","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/eji.201242529","volume":"43","author":"FJ Ward","year":"2013","unstructured":"Ward FJ, Dahal LN, Wijesekera SK et al (2013) The soluble isoform of CTLA-4 as a regulator of T-cell responses. Eur J Immunol 43:1274\u20131285","journal-title":"Eur J Immunol"},{"key":"2098_CR72","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA et al (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275\u2013287","journal-title":"Nat Rev Cancer"},{"key":"2098_CR73","doi-asserted-by":"publisher","first-page":"5916","DOI":"10.4049\/jimmunol.180.9.5916","volume":"180","author":"B Liang","year":"2008","unstructured":"Liang B, Workman C, Lee J et al (2008) Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 180:5916\u20135926","journal-title":"J Immunol"},{"key":"2098_CR74","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/eji.1830260533","volume":"26","author":"B Huard","year":"1996","unstructured":"Huard B, Prigent P, Pages F et al (1996) T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding. Eur J Immunol 26:1180\u20131186","journal-title":"Eur J Immunol"},{"key":"2098_CR75","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1089\/aid.2012.0195","volume":"30","author":"J Pena","year":"2014","unstructured":"Pena J, Jones NG, Bousheri S et al (2014) Lymphocyte activation gene-3 expression defines a discrete subset of HIV-specific CD8(+) T cells that is associated with lower viral load. Aids Res Hum Retrov 30:535\u2013541","journal-title":"Aids Res Hum Retrov"},{"key":"2098_CR76","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1093\/annonc\/mdx557","volume":"28","author":"S Burugu","year":"2017","unstructured":"Burugu S, Gao D, Leung S et al (2017) LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1\/PD-L1+ tumors. Ann Oncol Off J Eur Soc Med Oncol 28:2977\u20132984","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2098_CR77","doi-asserted-by":"publisher","first-page":"djw329","DOI":"10.1093\/jnci\/djw329","volume":"109","author":"MK Schmidt","year":"2017","unstructured":"Schmidt MK, van den Broek AJ, Tollenaar RA et al (2017) Breast cancer survival of BRCA1\/BRCA2 mutation carriers in a hospital-based cohort of young women. J Natl Cancer Inst 109:djw329","journal-title":"J Natl Cancer Inst"},{"key":"2098_CR78","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1471-2407-10-90","volume":"10","author":"L Cortesi","year":"2010","unstructured":"Cortesi L, Masini C, Cirilli C et al (2010) Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer. BMC Cancer 10:90","journal-title":"BMC Cancer"},{"key":"2098_CR79","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","volume":"17","author":"AM Gonzalez-Angulo","year":"2011","unstructured":"Gonzalez-Angulo AM, Timms KM, Liu S et al (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 17:1082\u20131089","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2098_CR80","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1200\/JCO.2008.19.9067","volume":"27","author":"M Kriege","year":"2009","unstructured":"Kriege M, Seynaeve C, Meijers-Heijboer H et al (2009) Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol Off J Am Soc Clin Oncol 27:3764\u20133771","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-02098-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-021-02098-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-02098-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T14:30:27Z","timestamp":1666449027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-021-02098-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,22]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["2098"],"URL":"https:\/\/doi.org\/10.1007\/s10147-021-02098-1","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2022,1,22]]},"assertion":[{"value":"21 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflicts of interest for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research project was approved by the Ethics Committee of Tianjin Cancer Institute and Hospital. Ethics approval for breast tumors, paired normal tissues as well as peripheral blood: use of breast tumors, paired normal tissues as well as peripheral blood was approved by the ethics committee of the Ethics Committee of Tianjin Cancer Institute and Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consents were obtained from each patient in accordance with the Declaration of Helsinki. Written consents were obtained from each patient to publish the pathological tissue images as representative figures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consents"}}]}}